RVPH (Reviva Pharmaceuticals Holdings) Interest Expense: $-0.01 Mil (TTM As of Mar. 2026)


RVPH Reviva Pharmaceuticals Holdings Inc RVPH
22 GF Score
Price $0.63
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings Interest Expense?

Reviva Pharmaceuticals Holdings RVPH -4.55% 22 Interest Expense is $-0.01 Mil as of Mar. 2026. GuruFocus rates RVPH with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Reviva Pharmaceuticals Holdings's interest expense for the three months ended in Mar. 2026 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Reviva Pharmaceuticals Holdings's Operating Income for the three months ended in Mar. 2026 was $ -3.27 Mil. Reviva Pharmaceuticals Holdings's Interest Expense for the three months ended in Mar. 2026 was $ -0.01 Mil. Reviva Pharmaceuticals Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Reviva Pharmaceuticals Holdings  (OTCPK:RVPH) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Reviva Pharmaceuticals Holdings's Interest Expense for the three months ended in Mar. 2026 was $-0.01 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-3.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.00 Mil.

Reviva Pharmaceuticals Holdings's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Reviva Pharmaceuticals Holdings did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Reviva Pharmaceuticals Holdings Interest Expense Historical Data

* Premium members only.

The historical data trend for Reviva Pharmaceuticals Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reviva Pharmaceuticals Holdings Interest Expense Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.00 0.00 -0.03 -0.02 -0.01

Reviva Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.00 0.01 -0.01
RVPH
22GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Reviva Pharmaceuticals Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.01 Mil mean?
Reviva Pharmaceuticals Holdings (RVPH) has a Interest Expense of $-0.01 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Reviva Pharmaceuticals Holdings and its competitors.
Is Reviva Pharmaceuticals Holdings' Interest Expense too high?
Reviva Pharmaceuticals Holdings' current Interest Expense is $-0.01 Mil. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Interest Expense compare to AIM and BOLT?
Reviva Pharmaceuticals Holdings' Interest Expense of $-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current Interest Expense is $-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Interest Expense of $-0.01 Mil. The current Interest Expense is $-0.01 Mil. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Interest Expense is $-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score

Get the complete analysis for RVPH

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price